SLC5A2 and chronic kidney disease: Among patients with CKD, AKI was less commonly observed in the SGLT-2 inhibitor arm compared with the placebo arm: RR 0.82 (95% CI 0.72–0.93; P = 0.003) (Fig. 5 and Table 3).